NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Emcure Pharmaceuticals Ltd. launched its initial public offering today and the offer will close for subscription on July 05. The pharma company has fixed the price band in the range of Rs 960-Rs 1008.
Issue size: The Rs 1,952 crore IPO consists of fresh issue of Rs 800 crore and offer for sale of Rs 1,150 crore by promoters and investor selling shareholder. The proceeds from the fresh issue will be used for repayment of debt.
View:
Emcure with leading position in the domestic therapeutic area, plans to increase its market share in both India and globally by focusing on its key brands, launching new differentiated products, increased focus on hospitals/pharmacy chains and persuing organic/inorganic growth.
The IPO is reasonably priced at 36.1 times FY24 P/E (on diluted basis). We believe commencement of new capacities and potential debt reduction post-IPO would aid recovery in profitability. Recommend Subscribe for Long Term.
Risk and Concerns
The company is subject to government regulations in India and in international markets.
Any slowdown or shutdown in manufacturing or R&D operations could adversely affect the business.
The company is dependent on third parties for the distribution and marketing of the products.
Any disruptions to the supply, or increases in the pricing, of the raw materials may adversely affect the business, cash flows, and financial condition of the company.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
